Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Wink Biotherapeutics

Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

Hallandale Beach (Florida), United States, North AmericaBiotech & life sciences, RNA aptamers – type 1 diabetes and solid tumors
Stage
Pre-seedNo documented AI
Product
R&DNone known
Funding raised
$125Kdisclosed
Founded
20233 years ago
Founders
2Warren, Paolo
Global score
3.5Grade DRank 111 of 151

Overview

Biotech company developing modified RNA aptamer therapies for type 1 diabetes (beta cell regeneration) and solid tumors.

Traction

None known

No public evidence of traction found: preclinical RNA aptamer pipeline.

Market

Aptamers (therapeutics and diagnostics)

Early therapeutics are bought by pharma through licensing after preclinical and early clinical proof. Type 1 diabetes therapies that restore beta cells would address a large unmet need beyond insulin. Funding at this stage comes from grants (NIH), accelerators and specialised biotech seed funds. Value inflects at IND-enabling data.

Addressable market

2025
$1.4B
2030
$3.2B
+18.1% a year

Aptamers (therapeutics and diagnostics): $1.4bn in 2025, ~18% CAGR (Grand View Research).

Customers

Pharma and biotech licensees in diabetes and oncology; later health systems

Who signs the cheque

Pharma business development; grant agencies and seed investors fund the path

Geographies

  • United States

Drivers

  • Unmet need for disease-modifying T1D therapy
  • Interest in non-antibody targeting modalities
  • Grant funding for academic spin-outs

Headwinds

  • Preclinical stage
  • Negligible capital
  • Long regulatory path

Grand View Research values aptamers at $1.4bn in 2025 and $5.3bn in 2033 (implied CAGR ~18%); range $1.4–8.6bn; 2030 extrapolated ~$3.2bn.

Scalability 5/10. Therapy with global reach once approved, but a preclinical pipeline and a long regulatory path.

Market source: dri.co.jp

Technology

Category

Therapeutics platform (RNA aptamers)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

Modified RNA aptamers licensed from the University of Miami bind targets to drive beta-cell regeneration in type 1 diabetes and to act on solid tumours. The pipeline is preclinical.

Moat

Exclusive licence and inventor involvement; defensibility depends on patent scope and in vivo data.

Differentiation

Aptamers are synthetic, cheaper to make and less immunogenic than antibodies.

Integration points

  • Stem-cell-derived beta-cell assays
  • CROs
  • Pharma diabetes programmes

Depends on

  • University licence
  • Preclinical models
  • GMP oligonucleotide manufacturing

Use of AI

No use of AI mentioned

Product in detail

Modified RNA aptamer platform licensed from the University of Miami.

Business

Model
Drug development with eventual licensing or partnership.
Revenue logic
Milestones and royalties; no revenue.
Go-to-market
Grant and accelerator funding, then pharma partnering.

Next milestones

  1. NIH SBIR award
  2. In vivo proof of beta-cell regeneration
  3. Seed round

Key risks

  • Preclinical failure
  • Funding gap
  • Licence dependence

Opportunities

3 found in the network

Concrete moves for Wink Biotherapeutics inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Investors 2

Customers1

Who could buy, or sell through

Use defined media for stem-cell beta-cell assays

Testing beta-cell regeneration needs reproducible stem-cell-derived models; Defined Bioscience sells defined, serum-free media that reduce variability. Wink gets more reliable assays, Defined gains a therapeutic-developer customer.

30%confidence

Evidence from the records

  • “type 1 diabetes (beta cell regeneration)”
  • “defined, serum-free culture media (e.g. HiDef-B8) and reagents for pluripotent stem cell culture”
If it works
More reproducible preclinical data and a customer case study.
First step
Ask Defined Bioscience for samples and protocols for beta-cell differentiation.

Investors2

A fund whose thesis fits

Apply for NIH SBIR funding

NIH funds US biotech and medtech via SBIR and backed network members Defined Bioscience, Corticale and Microvitality. Non-dilutive funding fits Wink's $75K capital base.

40%confidence

Evidence from the records

  • “Biotech & life sciences”
  • “Negligible capital”
If it works
Non-dilutive funding for in vivo proof-of-concept.
First step
Ask Defined Bioscience's founders about their NIH application and target the next SBIR deadline.

Pitch KDT Ventures once in vivo data exists

KDT invests $0.5–5M from pre-seed to Series A in US biotech and backed network member ZymoChem. It is a seed target after first in vivo data.

25%confidence

Evidence from the records

  • “Biotech & life sciences”
  • “Pre-seed”
If it works
A seed round for IND-enabling work.
First step
Request an intro via ZymoChem once animal data is available.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

US federal biomedical research agency funding biotech, health and medtech via SBIR and research grants (Defined Bioscience, Microvitality, Corticale).

US RNA aptamers for type 1 diabetes and tumours — NIDDK/NCI fit.

50%confidence

Evidence from the records

  • “"Biotech & life sciences"”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
First step
Prepare SBIR Phase I.

Physician-founded Austin VC ($250M+ AUM) backing science-driven therapeutics, digital health, industrial biotech and climate companies.

US RNA aptamers for type 1 diabetes and solid tumours — therapeutics at pre-seed.

50%confidence

Evidence from the records

  • “therapeutics”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send a science summary to the partners.

US angel network investing at pre-seed and seed; backed Vytala Health's $805K pre-seed in medical nutrition.

US pre-seed aptamer therapeutics — biotech, very early.

20%confidence

Evidence from the records

  • “Vytala Health”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via Vytala Health (network portfolio company of JumpStart NJ Angel Network).
First step
Low priority.

Investor with no public profile in our data; its only known deal is an $8M pre-Series A extension in BioSapien.

US RNA aptamer therapeutics at pre-seed — sector-adjacent, likely too early.

15%confidence

Evidence from the records

  • “BioSapien”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Low priority.

Argentine VC that invested in Nanogrow Biotech's US$1.2M seed; thesis and ticket otherwise undocumented.

RNA aptamers for type 1 diabetes and tumours: biotherapeutic platform like Nanogrow, but US-based.

15%confidence

Evidence from the records

  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “Pre-seed”

Holding that invested in BioSapien's US$5.5M pre-Series A (oncology drug delivery); profile is undocumented.

RNA aptamers including solid tumours: oncology overlap, preclinical.

15%confidence

Evidence from the records

  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “Pre-seed”

Korean government drug-development fund supporting Korean biotech pipelines, including a 2026 grant to BILIX.

US aptamers — no Korean entity.

10%confidence

Evidence from the records

  • “South Korea”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Low priority.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption7.0/10
Business model1.0/10
Market4.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early to invest.

Disruption

7/10

RNA aptamers to regenerate beta cells: a new approach.

Business model

1/10

Preclinical pipeline, no revenue.

Market

4/10

Score 4/10: TAM $1.4bn → base 4; scalability 5/10 (0); no commercial presence in ≥2 countries yet (0).

Risk

9/10

Lower is better

Very high risk: preclinical with $0.1M raised.

Strengths

  • Original science
  • Huge markets

Risks

  • Preclinical
  • Negligible capital

Funding

$125K, disclosed
  1. 2023-07-06

    acceleratornot disclosed

    not disclosed (Caplight; likely StartUp Health)

  2. 2024-12-09

    grantnot disclosed (~$30K by difference)

    not disclosed (Caplight)

  3. 2025-05-19

    pre-seed$75K

    StartUp Health, Dreamward Ventures

  4. 2025-06-27

    prize (Sloss.Tech/Ideas Pitch Competition, Grand Prize)$50,000

    Sloss Tech / Regions Foundation

  5. 2026

    prize (WHX Miami Xcelerate Startup Competition – grand prize: sponsored exhibition at WHX Dubai 2027, booth at WHX Miami 2027, 30-day executive mentoring)non-monetary

    WHX Miami / City of Miami Beach

Amount used in the study. $75K pre-seed + $50K Sloss Tech prize; ~$30K grant (inferred) as upper bound.

Note. Conflicting sources: $75K (pre-seed, Caplight) or $105K total (Caplight); + $50K Sloss Tech prize

The 2026 prize in Miami Beach is the grand prize of the WHX Miami Xcelerate Startup Competition (not SPARC Ignite); CEO confirmed: Warren D. Marcus, PhD. No SWC 2026 qualification found.

Team

  • Warren Marcus

    Co-founder & CEO

    PhD; identified the RNA aptamer technology against diabetes at the University of Miami and licensed it into Wink.

  • Paolo Serafini

    Co-founder & inventor of the technology

    PhD, associate professor (University of Miami), inventor of the RNA aptamer platform.

Sources

Identification confidence
high
  1. 1convention.bio.org/2026-sessions-and-courses/wink-biotherapeutics
  2. 2caplight.com/company/winkbiotx
  3. 3convention.bio.org/speakers/warren-marcus
  4. 4miamibeachfl.gov/miami-beach-helps-spotlight-the-future-of-healthcare-innova

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet